GlassScriptPhysician profile
Emily Hammonds
NPI 1083330971
$5,848.70
in general payments reported to CMS, 2019-2025
25 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $68.56 · 2023: $1,450 · 2024: $2,659 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,780.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.02 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $537.85 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $443.13 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $403.78 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $402.68 | 2022-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $381.47 | 2022-2025 | |
| Pfizer INC. | $361.16 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $345.05 | 2023-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $311.80 | 2023-2025 | Relistor, Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $311.21 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.51 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $256.34 | 2023-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $231.18 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Grifols USA, LLC | $176.99 | 2022-2025 | Prolastin-C Liquid |
| Kowa Pharmaceuticals America, INC. | $162.06 | 2023-2024 | Livalo, Seglentis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.97 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $86.55 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $77.93 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $72.31 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $49.58 | 2023-2025 | Gvoke Hypopen |
| Ardelyx, INC. | $36.44 | 2024-2025 | Ibsrela |
| Verona Pharma, INC. | $36.39 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $22.98 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $14.88 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $13.44 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hammonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.